SCHEDULE: Five Narrow Lane LP Discloses 9.99% Beneficial Ownership in Oragenics, Inc.
Beneficial Ownership Disclosure
Five Narrow Lane LP has filed a Schedule 13G, reporting a 9.99% beneficial ownership stake in Oragenics, Inc., representing 82,210 shares.
Summary
- Five Narrow Lane LP, based in New York, has reported beneficial ownership of 82,210 shares of Oragenics, Inc. common stock.
- This ownership represents 9.99% of Oragenics, Inc.'s outstanding common stock.
- The calculation of the percentage is based on 822,927 shares outstanding as of June 23, 2025, as disclosed in a Form S-1 filed by Oragenics, Inc.
- Five Narrow Lane LP's aggregate beneficial ownership is contractually restricted to a maximum of 9.99% of the class.
- The shares were not acquired and are not held for the purpose of changing or influencing the control of Oragenics, Inc., nor in connection with any transaction having that purpose or effect, other than activities solely related to a nomination under SEC Rule 240.14a-11.
Sentiment
Score: 5
Explanation: The document is a factual regulatory disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or prospects.
Positives
- The reporting person, Five Narrow Lane LP, explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing the control of Oragenics, Inc., indicating stability in current management.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by Five Narrow Lane LP in Oragenics, Inc., a common occurrence in the public markets where institutional investors acquire stakes in companies. The stated purpose of not seeking control aligns with typical passive investment strategies, distinguishing it from potential activist investor filings.
Stakeholder Impact
- Shareholders: The disclosure of a new significant shareholder holding 9.99% of the common stock may be viewed positively as a vote of confidence, especially given the stated intent not to seek control, which could imply stability.
Key Dates
| Date | Description |
|---|---|
| June 23, 2025 | Date as of which 822,927 shares of Oragenics, Inc. common stock were reported outstanding, per a Form S-1 filing. |
| July 02, 2025 | Date of the event which required the filing of this Schedule 13G statement. |
Keywords
Oragenics Inc., Five Narrow Lane LP, Beneficial Ownership, Schedule 13G, Common Stock, SEC Filing, Investment, Shareholder
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.